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Cytochrome b-561 in chromaffin granules interacts with antimycin and its a-peak shifts 1 nm towards red. 
When chromaffin granules were treated with Triton X-100 antimycin o effect was observed. Cytochrome 
b-561 is located in the plasma membrane isolated from the chromaffin cells. The plasma membrane b-561 
does not seem to interact with antimycin. A number of NADH or NADPH (acceptor) oxidoreductase 
activity has been observed in isolated plasma membrane providing clues to the origin of plasma membrane 
dehydrogenase. The possible role of cytochrome b-561 in secretory granules other than its accredited 
energy conserving electron transport property is projected. 
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1. INTRODUCTION 
Cytochrome b-561 is present in chromaffin 
granules [I], serotonin-dense granules [2] and in 
noradrenaline storage vesicles [3]. The 
physiological role of cytochrome b-561 in these 
organelles remains obscured although its function 
in mitochondria is well-founded. In spite of best 
efforts by several groups [4-61 no meaningful role, 
in terms of physiological function of chromaffin 
granules, has been assigned to cytochrome b-561, 
mainly due to its location; i.e., facing the cytosolic 
exterior [7]. However, it is known that in chromaf- 
fin granules cytochrome b-561 can be oxidized by 
ferricyanide, can be reduced by ascorbate [S] and 
has a midpoint potential of + 140 mV at pH 7.0 
[9]. Furthermore, cytochrome b-561 in chromaffin 
granules does not accept electrons from NADH 
and its endogenous oxidase remains to be iden- 
tified. In isolated chromaffin cell plasma mem- 
brane, cytochrome b-561 activity and its reducibili- 
ty with NADH was identified together with latent 
NADH-cytochrome b-561 reductase activity 
(A.N.M., T. Flatmark, in preparation). Here, we 
confirm the location of cytochrome b-561 in 
chromaffin cell plasma membrane and present 
evidence for the occurrence of a number of 
NADH/NADPH (acceptor) oxidoreductases. 
The u~queness of cytochrome b-561 in 
mitochondria [lo] is its interaction with antimycin 
causing a spectral shift towards red. We report that 
cytochrome b-561 in chromaffin granules interacts 
with antimycin and an obvious spectral shift oc- 
curs. But with cytochrome b-561 in plasma mem- 
brane one does not see the antimycin effect. The 
possible function of cytochrome b-561 in secretory 
organelles other than its energy-conse~ing elec- 
tron transport property is postulated. 
2. ~PERIME~AL 
The chromaffin granules from bovine adrenal 
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medulla were prepared according to [l l] as 
modified in [12]. The plasma membrane from the 
chromaffin cells were isolated essentially as in [ 131, 
except that in the final step plasma membrane frac- 
tion was collected at the interphase of 1.0-1.2 M 
sucrose in a discontinuous gradient after cen- 
trifugation at 150000 x g for 14 h. NADH or 
NADPH (acceptor) oxidoreductase activity was 
measured as in [ 141. Cytochrome c oxidase assay 
was done as recommended in [ 151. Difference spec- 
tra (reduced minus oxidized) were recorded utiliz- 
ing Aminco DW-2 and Beckman Acta III spec- 
trophotometers. The protein was determined as in 
[ 161 employing bovine serum albumin as standard. 
All enzyme assay and difference spectroscopic 
studies were performed in thermostated cuvettes at 
30°C. Cytochrome c (horse heart type VI), glyox- 
ylate, antimycin A, dichloroindophenol, 
NADH/NADPH (each in 1 mg pre-weighed vials) 
and rotenone were from Sigma. Other reagents 
were of analytical grade. 
3. RESULTS 
Fig. 1. illustrates the interaction between 
cytochrome b-561 and antimycin A in chromaffin 
granules. The difference spectrum, ascorbate 
reduced minus oxidized was recorded (trace B), the 
addition of antimycin (trace C) induced a shift of 
the a-peak from 561 nm to 562 nm; when ascorbate 
was added to the reference cuvette (trace D) the 
resultant spectrum of antimycin-shifted b species 
with the a-peak at 562 nm was seen. Fig.2 il- 
lustrates the antimycin effect on cytochrome b-561 
in chromaffin granules treated with Triton X-100 
(trace B reduced minus oxidized). The addition of 
antimycin to the sample cuvette (trace C) did not 
shift the a-peak. Fig.3 shows the difference spectra 
of cytochrome b-561 in isolated plasma mem- 
brane: trace B is the ascorbate reduced minus ox- 
idized spectrum; and the addition of antimycin 
leaves cytochrome b-561 unaffected (trace C). 
Likewise, when plasma membrane was treated 
with Triton X-100 no spectral shift due to an- 
timycin was observed (not shown) indicating non- 
interaction of plasma membrane b-561 with 
antimycin. 
The extent of reduction of cytochrome b-561 in 
chromaffin granules as compared to the plasma 
membrane is illustrated in table 1. In chromaffin 
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Fig. 1. Difference spectra of chromaffin granules: 
50 mM phosphate buffer (pH 7.0) reduced by ascorbate 
(10 mM) and oxidized by ferricyanide (10 pM); (A) 
oxidized/oxidized; (B) reduced/oxidized; (C) reduced + 
antimycin (5 pM)/oxidized showing spectral shift of 
1 nm in cytochrome b-561; (D) ascorbate + 
antimycin/ascorbate. Antimycin was dissolved in 95% 
ethanol and an equal amount of ethanol was added to 
the reference cuvette in the case of (C). Baseline 
corrections were made. Chromaffin granules were 
present in 1.16 mg protein/ml. 
granules, about 93% cytochrome was reduced by 
ascorbate taking dithionite reduction as 100%. 
While in plasma membrane slightly lower reduc- 
tion was obtained. The two membranes were in- 
fluenced differently with respect to b-561 
reducibility in the Triton-treated system. In 
chromaffin granules Triton treatment did not 
enhance ascorbate reducibility while the reduction 
by dithionite was slightly decreased. This may be 
attributed to the non-specific perturbation of 
chromaffin granules caused by the detergent or the 
solubilization of some component of secretory 
system interacting with dithionite and interfering 
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Fig.2 Difference spectra of chromaffin granules. The 
experimental conditions were the same as in fig. 1, except 
that the chromaffin granules were treated with Triton 
x-100 (1%): (A) oxidized/oxidized; (B) 
ascorbate/oxidized; (0 ascorbate + 
antimycin/oxidized. Chromaffin granules were 1.05 mg 
protein/ml. 
spectrally. On the contrary, there was nearly a 
2-fold increase in the reduction and specific con- 
tent of cytochrome b-561 in the plasma membrane 
upon Triton treatment both with ascorbate or 
dithionite employed as reductant. A ratio ranging 
from 0.14-0.39 of plasma membrane : chromaffin 
granules b-561 specific content suggests the actual 
localization of this protein in the plasma mem- 
brane and not an artefact of preparation. 
Table 2 summarizes various acceptor ox- 
, * 
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Fig.3. Difference spectra of plasma membrane. The 
experimental conditions were the same as in fig. 1: (A) 
oxidized/oxidized; tB) ascorbate/oxidized; CC) 
ascorbate + antimycin/oxidized. Plasma membranes 
were present in 1.22 mg protein/ml. 
idoreductase activities in 3 representative prepara- 
tions of plasma membrane. There was no detec- 
table cytochrome c oxidase activity present and 
neither NADPH cytochrome c reductase nor 
rotenone-sensitive NADH cytochrome c reductase 
activity were found. The NADH dehydrogenase 
system responsible for reduction of ferricyanide or 
dichloroindophenol showed large activities as com- 
pared to NADPH-linked dehydrogenase, with the 
exception of dehydrogenase catalyzing glyoxylate 
reduction. The ratio of NADH-ferricyanide reduc- 
tase: NADH cytochrome c reductase activity was 
4.0, according to the data in table 2 (a mean value 
of the 3 preparations), while in chromaffin 
granules this ratio was 0.4 [17], indicating that this 
is plasma membrane dehydrogenase. 
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Table 1 Table 2 
Specific activity of cytochrome b-561 in chromaffin 
granules (CG) as compared with the plasma membrane 
Acceptor oxidoreductase activity in plasma membrane 
of chromaffin cells 
(PM) 
Reductant CG PM 
PM 
(nmol/mg protein) cc 
Acceptor oxidoreductase Spec. act. 
(nmol , mitt-’ . mg protein- ‘) 
Prep.(a) Prep.(b) Prep.(c) 
Ascorbate 
Ascorbate + l%‘o 
0.088 0.013 0.147 
26.8 
Triton X-100 
Dithionite 
Dithionite + 1% 
0.084 0.025 0,297 
0.095 0.015 0.157 
NADH - 
cytochrome c 
NADPH - 
cytochrome c nil 
8.4 
Triton X-100 0.082 0.032 0.390 
These values are based on reduced minus oxidized 
difference spectra employing 26.8 mM_' . cm-’ as molar 
extinction coefficients at the wavelength pair 
561-575 nm [18]. The membrane preparation was 
oxidized with ferricyanide (10&Q, and ascorbate was 
NADH - 
glyoxylate 
NADPH - 
glyoxylate 8.4 
NADH - 
ferricyanide 
NADPH - 
ferricyanide 
132.9 
12.9 
10 mM 
4. DISCUSSION 
NADH - 
dichloroindophenol 
NADPH - 
dichloroindophenol 
34.0 
4.0 
Cytochrome b-561 in chromaffin granules faces 
cytoplasmic exterior and is ascorbate reducible in 
situ. It does not interact with internal cytochrome 
c, nor does it accept electrons donated by NADH 
in chromaffin granules [5]. It seems that in 
secretory granules it has one side of reduction. As 
shown in table 1, ascorbate reduced almost all the 
moiety, and upon Triton treatment no reducible 
b-561 component was rendered available. On the 
contrary, in plasma membrane the orientation of 
cytochrome b-561 appears to be markedly dif- 
ferent from that in chromaffin granules. The 
Z-fold rise in specific content of cytochrome b-561 
due to Triton treatment supports this statement. 
Fu~hermore, the reducibility of b-561 by NADH 
and the recognition of latent NADH cytochrome 
b-561 reductase activity (in preparation) indicate 
more than a single side of reduction. 
SO mM phosphate buffer (pH 7.0), NADH (lemma, 
NADPH (lOOpM), cytochrome c (SO FM), glyoxylate 
(4 mM), ferricyanide (100 pM), dichloroindopheno~ 
(1~~M). In cytochrome c reductase assay 3 mM 
sodium cyanide was present. The total volume of the 
reaction mixture was 1.0 ml. NADH-cytochrome c 
reductase activity was insensitive to rotenone, 
Preparation (a), (b) and (c) contained 30.7, 32.5 and 
28.5 pg protein/ml in the reaction cuvette, respectively 
In secretory granules cytochrome b-561 interacts 
with antimycin and its a-peak shifts towards red by 
1 nm. Moreover, when chromaffin granules were 
treated with 1Yo Triton X-100 cytochrome 6-561 
does not see antimycin effect. Similarly in plasma 
membrane cytochrome b-561 does not interact 
with antimycin either in intact membrane, or mem- 
brane treated with 1% Triton X-100. Thus, it ap- 
pears that the reactivity of antimycin with a redox 
protein like b-561 is solely due to the latter’s orien- 
tation in the membrane as envisaged by the 
chemiosmosis concept. These findings are contrary 
to the observation in [lg] where antimycin effects 
on b-561 in chromaffin granules were not seen. 
Furthermore, non-reduction of b-561 in chromaf- 
fin granules by durohydroquinone [lS] is a weak 
criterion for distinction between chromaffin 
granules vs mitochondrial c~~hrome, since’ the 
endogenous oxidase system for chromaffin 
granules b-561 remains unknown. It is evident here 
that cytochrome b-561 in chromaffin granules 
shares the property of mitochondrial b-561 
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towards its interaction with antimycin. Myx- 
athiozol (M), another site II inhibitor of mitochon- 
drial electron transport blocking the antimycin- 
insensitive site in ~tochondria, does not interact 
with mitochondrial b-561. Likewise, b-561 in 
chromaffin granules does not show a myxathiozol 
effect [20]. Thus, b-561 in its native membrane 
orientation shares similar inhibitor effects in 
chromaffin granules and in mitochond~a. This is 
the first report showing the presence of 
cytochrome b-561 in chromaffin cell plasma mem- 
brane although plasma membrane from 
neutrophils [22] and milk fat globules [23] were 
shown to contain the b-type cytochrome. But the 
detailed knowledge of b-561 in plasma membrane 
as compared to chromaffin granules will have to 
await future experimentation. Commenting on the 
mitochondrial b-561 vs b-561 in chromaffin 
granules, there is not sufficient detailed structural 
information on granule b-561 to establish any in- 
trinsic difference or similarity between the two 
proteins (cf. 1181). Nevertheless, it may be argued 
that b-561 in chromaffin granules does not seem to 
participate in the actual physiological function of 
this organelle, while in mitochondria it has a ge- 
nuine role in electron transport coupled to proton 
translocation. 
What function may be assigned to a redox pro- 
tein like b-561 other than energy-conserving elec- 
tron transport in secretory granules or in plasma 
membrane? The folIowing possibilities are worthy 
of consideration: 
(i) Oxidoreduction causing conformations 
change in the protein affecting its binding to a 
receptor, or membrane permeability; 
(ii) Transmembrane oxidoreduction (can b-561 
species be attacked on more than one side of 
the membrane?); 
(iii) Alterations in membrane-fixed charge, both 
by the redox changes and by Bohr effect; 
(iv) Acting as or fuelling redox-linked pumps (not 
necessarily potential-generating proton 
pumps). 
NADH or NADPH dehydrogenases are intrinsic 
plasma membrane dehydrogen~es f 171. However, 
their origin in plasma membrane remains less 
known than the widely documented mitochondrial 
or microsomal dehydrogenases. Here a systematic 
study is reported on NADH/NADPH 
dehydrogenase in chromaffin cell plasma mem- 
brane employing a natural acceptor such as 
cytochrome c, a metabolic acceptor such as glyox- 
ylate and an artificial acceptor such as ferricyanide 
or dichloroindophenol (table 2). Since no 
cytochrome c oxidase activity was detected, it is 
safe to conclude that the plasma membrane 
preparation was not contaminated by mitochon- 
dria. This is further supported by the observed 
rotenone-insensitive NADH cytochrome c reduc- 
tase activity. The absence of NADPH cytochrome 
c reductase activity does exclude the possibility of 
microsomal contamination. 
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